Clinical Trial Update: A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers [Phase 1]

View source ↗

Summary

A first-in-human Phase 1a/1b study of CT-202, a nectin-4 directed bispecific antibody, in patients with recurring triple-negative breast cancer, colorectal canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Triple-negative Breast Cancer
• Urothelial Cancer

Drugs mentioned

• CT-202

Snippet

Sponsor: Context Therapeutics Inc. | Conditions: Triple Negative Breast Cancer (TNBC), Colorectal Cancer | Phase 1 | Status: NOT_YET_RECRUITING